No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma

International Journal of Gynecological Cancer

Volumn 13, Issue 2, 2003, Pages 192-196

  Baykal, Cem ^a,c   Ayhan, A ^b,b   Al, A ^a   Yuce K ^b  

^a SSK Ankara Maternity Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Cervical carcinoma; FHIT; Immunohistochemistry; Prognosis

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; ACID ANHYDRIDE HYDROLASE; TUMOR PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 0037969774     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13055.x     Document Type: Article

References (29)

1. Ohta M, Inoue H, Cotticelli MG et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
2. 3-triphosphate hydrolase. Biochemistry 1996;35:11529-35.
3. Druck T, Hadaczek P, Fu TB et al. Structure and the expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-12.
4. Thiagalingam S, Lisitsyn NA, Hamaguchi M et al. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996;56:2936-9.
5. Yanagisawa K, Kondo M, Osada H et al. Molecular analysis of the FHIT gene at the 3p14; 2 in lung cancer cell lines. Cancer Res 1996;56:5579-82.
6. Negrini M, Monaco C, Vorechovsky I et al. The FHIT gene at 3p14; 2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-9.
7. Virgilio L, Shuster M, Gollin SM et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996;93:9770-5.
8. Mao L, Fan YH, Lotan R, Hong WK. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 1996;56:5128-31.
9. Sozzi G, Veronesse ML, Negrini M et al. The FHIT gene at 3p14; 2 is abnormal in lung cancer. Cell 1996;85:17-26.
10. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial and cervical cancer cell lines. Cancer Res 1997;57:2112-5.
11. Hayashi S, Tanimoto K, Hajironakanishi K et al. Abnormal FHIT transcripts in human breast carcinomas. A clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 1997;57:1981-5.
12. Druck T, Hadaczek P, Fu TB et al. Structure and expression of human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-12.
13. Panogopoulos I, Thelin S, Mertens F, Mitelman F, Aman P. Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosome Cancer 1997;19:215-9.
14. Lisitsyn NA, Lisitsina NM, Dalbagni G et al. Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci USA 1995;92:151-5.
15. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathologic significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998;58:5478-83.
16. Hadaczek P, Sipirashvili Z, Markiewski M et al. Absence or reduction of FHIT expression in most clear cell renal carcinomas. Cancer Res 1998;58:2946-51.
17. Sozzi G, Sard L, Gregorio LD et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121-3.
18. Yoshino K, Enomoto T, Nakamura T et al. FHIT alterations in cancerous and noncancerous cervical epithelium. Int J Cancer 2000;85:6-13.
19. Krivak TC, McBroom JW, Seidman J et al. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. Cancer Res 2001;61:4382-5.
20. Helland A, Kraggerud SM, Kristensen GB et al. Primary cervical carcinomas show 2 common regions of deletion at 3P,1 within the FHIT gene: evaluation of allelic inbalance at FHIT, RB1 and TP53 in relation to survival. Int J Cancer 2000;88:217-22.
21. International Federation of Gynecology and Obstetrics (FIGO) Cancer Committee. Staging announcement. Gynecol Oncol 1986;25:383-9.
22. Greenspan DL, Connolly DC, Wu R et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997;57:4692-8.
23. Jones MH, Nakamura Y. Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphism. Oncogene 1992;7:1631-4.
24. Kohno T, Takayama H, Hamaguchi M et al. Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene 1993;8:1825-32.
25. Su TH, Wang JC, Tseng HH et al. Analysis of FHIT transcripts in cervical and endometrial cancers. Int J Cancer 1998;76:216-22.
26. Yoshino K, Enomoto T, Nakamura T et al. FHIT alterations in cancerous and noncancerous cervical epithelium. Int J Cancer 2000;85:6-13.
27. Birrer M, Hendricks D, Farley J et al. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999;59:5270-4.
28. Yoshino K, Enomoto T, Nakamura T et al. Aberrant Fhit transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer 1998;76:171-6.
29. Nakagawa S, Yoshikawa H, Kimura M et al. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer 1999;79:589-94.